Search clinical trials for: Genomic driven chemotherapy

Total 13605 results

Yonsei University
Samsung Medical Center; AstraZeneca; Seoul National University Hospital; Korean... and other collaborators

Recruiting

An uMbrella Study of BIomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent OvariaN Cancer(AMBITION)

Platinum-resistant Recurrent Ovarian Cancer

Korea, Republic of
Gustave Roussy, Cancer Campus, Grand Paris
Institut Curie

Completed

Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer (REMAGUS04)

Breast Cancer

France
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

Israel, Taiwan, United States, Australia, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART B)

Acute Lymphoblastic Leukemia | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic...

Netherlands
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies (HEM-iSMART C)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
The Christie NHS Foundation Trust
Prostate Cancer UK

Recruiting

Hypoxia-driven Prostate Cancer Genomics (HYPROGEN) (HYPROGEN)

Hypoxia | Prostate Cancer

United Kingdom
AstraZeneca

Recruiting

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations (AVANZAR)

NSCLC

China, United States, United Kingdom, Korea, Republic of, Italy, Hungary, Spain, Vietnam, France, Brazil, Canada, Japan, Taiwan, Germany, Austria, Turkey, India, Peru, Poland, Sweden, Bulgaria, Greece, Mexico, Denmark
Princess Maxima Center for Pediatric Oncology
Innovative Therapies For Children with Cancer Consortium; IBFM; Fight Kids Cancer

Not yet recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies (HEM-iSMART D)

Acute Lymphoblastic Leukemia, in Relapse | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent | Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory | Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Refractory

Netherlands
Singlera Genomics Inc.
Second Affiliated Hospital, School of Medicine, Zhejiang University

Recruiting

ctDNA Methylation Application in Postoperative Relapse and Adjuvant Chemotherapy Efficacy Evaluation

Cancer Colorectal

China
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Argentina, Hong Kong, Chile and more
Centre Hospitalier Universitaire de Nice
Jazz Pharmaceuticals; Acute Leukemia French Association

Recruiting

CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics (ALFA2101)

Acute Myeloid Leukemia

France
Shanghai Zhongshan Hospital

Not yet recruiting

Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

Sensitivity
Sophia Genetics SAS

Recruiting

Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer (DEEP-Lung-IV)

Non-small Cell Lung Cancer Metastatic

United States, Spain, France, Israel, Germany, Canada, Italy, Brazil
Merck Sharp & Dohme LLC

Recruiting

Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008)

Colorectal Cancer

United States, Belgium, Canada, Germany, Italy, Korea, Republic of, Poland, Russian Federation, Spain, Turkey, United Kingdom, France, Denmark, Romania, Estonia, Hungary, Guatemala, Costa Rica, Lithuania, Greece, Colombia, Netherl...
Guangdong Association of Clinical Trials

Not yet recruiting

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Non-Small-Cell Lung Cancer
Hellenic Cooperative Oncology Group

Recruiting

Effects of Cytotoxic Chemotherapy and PARP Inhibition on the Genomic Contexture of Ovarian Cancer

Ovarian Cancer

Greece
Gencurix, Inc.

Recruiting

Clinical High and Genomic Low Hormone Receptor-positive Early Breast Cancer Patients With or Without Adjuvant Chemotherapy

Early Hormone Receptor-positive Breast Cancer

Korea, Republic of
University Hospital, Gasthuisberg
University Hospital, Ghent; University Hospital, Antwerp; Academisch Medisch...

Recruiting

Genomic and Epigenomic Alterations After Cancer Treatment in Pregnancy (GE-CIP)

Cancer | Pregnancy

Belgium
West German Study Group
Novartis; Genomic Health®, Inc.

Recruiting

Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (ADAPTcycle)

Breast Cancer Female

Germany
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Recruiting

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)

Metastatic Colorectal Cancer

Australia, United States, Belgium, China, Japan, Canada, Denmark, France, Norway, Romania, Spain, United Kingdom, Austria, Brazil, Germany, Netherlands, Argentina, Czechia, Ireland, Italy, Turkey, Chile, Greece, Puerto Rico
Karolinska Institutet
The Swedish Research Council; AstraZeneca; Janssen Pharmaceutica N.V., Belgium; Kom Op Tegen Kanker and other collaborators

Recruiting

ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (ProBio)

Metastatic Castration-resistant Prostate Cancer (mCRPC) | Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Sweden, Belgium, Switzerland, Norway
Sunnybrook Health Sciences Centre

Recruiting

Genomic Markers for Measuring Breast Cancer Response to Neoadjuvant Chemotherapy

Breast Cancer | Breast Neoplasms | Cancer, Breast

Canada
Central Hospital, Nancy, France
Institut National de la Santé Et de la Recherche Médicale, France; French Innovative...

Recruiting

Genomic and Proteomic Study of Richter Syndrome (CGPSR) (CGPSR)

Richter Syndrome

France
Samsung Medical Center
Samsung Genomic Institute

Recruiting

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study III

Lymphoma, Non-Hodgkin | Lymphoma, Hodgkin

Korea, Republic of
Dr. Frank Arguello Cancer Clinic
Instituto de Ciencia y Medicina Genomica, Torreon, Coah. Mexico www.institutodeciencia...

Recruiting

Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)

Neoplasms

Mexico
Razor Genomics
Encore Clinical

Recruiting

Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States, France, Germany
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

Medulloblastoma

United States, Canada, Saudi Arabia, Puerto Rico, Australia
Genentech, Inc.

Completed

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response (MyTACTIC)

Advanced Unresectable or Metastatic Solid Malignancy

United States
University Hospital, Rouen
Institut Curie

Active, not recruiting

Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy (SELECT)

Bladder Cancer | Genomic Instability

France
University of Texas Southwestern Medical Center
BerGenBio ASA; Translational Genomics Research Institute; Triligent International

Terminated

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

Cancer of Pancreas

United States
University of Nebraska
National Cancer Institute (NCI); Spectrum Pharmaceuticals, Inc

Completed

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Hepatosplenic T-cell Lymphoma

United States
Hoffmann-La Roche
Breast International Group; Frontier Science & Technology Research Foundation... and other collaborators

Completed

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030)

Triple Negative Breast Cancer

Russian Federation, United States, Israel, Italy, Spain, France, Korea, Republic of, United Kingdom, Denmark, Taiwan, Hungary, Argentina, Australia, Austria, Belgium, Brazil, China, Germany, Hong Kong, Japan, Mexico, Romania, Switze... and more
UNICANCER
Myriad Genetics, Inc.

Completed

Prospective Study Assessing EndoPredict® Genomic Test Impact on Shared Decision of Adjuvant Chemotherapy in Patients With ER-positive, Her2-negative Early Breast Cancer (ADENDOM)

Breast Cancer
zr Pharma & GmbH
Foundation Medicine

Completed

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

Ovarian Cancer | Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer

United Kingdom, United States, Israel, Spain, Italy, Czechia, Canada, Hungary, Poland, Russian Federation, Brazil, Ukraine
UNICANCER

Active, not recruiting

Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (ASTER 70s)

Breast Cancer

France, Belgium
Royal Marsden NHS Foundation Trust
Merck KGaA, Darmstadt, Germany; University of Oxford; University of Surrey

Terminated

Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer (POLEM)

Microsatellite Instability | Stage III Colon Cancer | POLE Exonuclease Mutant Colon Cancer

United Kingdom
Institut Curie
Servier; UNICANCER

Completed

Comparison Between Fotemustin to Intensive Surveillance in Patients With High Risk Uveal Melanoma (FOTEADJ)

Uveal Melanoma

France, Switzerland
Icahn School of Medicine at Mount Sinai

Terminated

Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer

Colon Cancer | Medullary Thyroid Cancer

United States
Affiliated Hospital of Qinghai University
LanZhou University; Qinghai People's Hospital

Completed

The Relationship Between Microsatellite Instability and Efficacy of Fluorouracil Based Adjuvant Chemotherapy in Gastric Cancer After Operation

Gastric Cancer

China
University of Washington
National Cancer Institute (NCI)

Completed

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Refractory Acute Leukemia of Ambiguous Lineage | Recurrent Acute Leukemia of Ambiguous Lineage

United States
Samsung Medical Center

Completed

Study of Pembrolizumab in Metastatic Biliary Tract Cancer as Second-line Treatment After Failing to at Least One Cytotoxic Chemotherapy Regimen: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes

Biliary Tract Cancer

Korea, Republic of
Instituto Nacional de Ciencias Medicas y Nutricion...
Instituto Nacional de Medicina Genomica

Completed

Prospective Determination of COVID-19 Infection Rate in a Chemotherapy Unit in Mexico.

Cancer | Covid19 | Tumor

Mexico
Hoffmann-La Roche

Completed

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (MODUL)

Colorectal Cancer

France, Italy, Korea, Republic of, United Kingdom, Belgium, Argentina, Denmark, Germany, Greece, Netherlands, Poland, Slovenia, Spain, Sweden, Turkey, Brazil, Bosnia and Herzegovina, Mexico, Portugal, Egypt, Russian Federation, Se... and more
Carmel Medical Center

Active, not recruiting

Genome Driven Primary Care Clinics - an RCT

Microbial Colonization | Genetic Predisposition | Health Services Administration

Israel
Abramson Cancer Center of the University of Pennsylvania

Completed

A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
University of Turin, Italy

Unknown

The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial (EPIC)

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms | Stage IV, NSCLC

Italy
Yonsei University
National Cancer Center, Korea; Samsung Medical Center; AstraZeneca; Seoul National... and other collaborators

Unknown

A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) (KGOG3046)

Ovarian Cancer Stage IIIC | Ovarian Cancer Stage IV

Korea, Republic of
Sun Yat-sen University
The Second Affiliated Hospital of Kunming Medical University

Completed

The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival

Colorectal Cancer Metastatic | Microsatellite Instability High | Mismatch Repair Deficiency

China
M.D. Anderson Cancer Center

Completed

Registry Study for Personalized Cancer Therapy

Solid Tumors | Advanced Cancers

United States
National Taiwan University Hospital
Ono Pharmaceutical Co. Ltd; TTY Biopharm; ACT Genomics

Unknown

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer

Search clinical trials for: Genomic driven chemotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations